Association of Longitudinal Changes in Symptoms and Urinary Biomarkers in Patients with Urological Chronic Pelvic Pain Syndrome: A MAPP Research Network Study

Roy, Roopali; Stephens, Alisa; Daisy, Cassandra; Merritt, Lauren; Newcomb, Craig; Yang, Jiang; Dagher, Adelle; Curatolo, Adam S.; Sachdev, Monisha; McNeish, Brendan; Landis, Richard; Bokhoven, Adrie van; El-Hayek, Andrew; Froehlich, John W.; Pontari, Michel A.; Zurakowski, David; Lee, Richard S.; Moses, Marsha A.

doi:10.1097/ju.0000000000001391

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Studied in urological chronic pelvic pain syndrome and have been shown to positively correlate with severity of pain and symptoms in women with this pathology. [ 35–38 ] Neutrophil gelatinase-associated lipocalin (NGAL; also known as LCN 2) Released by neutrophils in response to tissue inflammation and infection. Studied in urological chronic pelvic pain syndrome.…”

Section: Literature Review Of Chronic Pain Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

How Well Do Current Laboratory Biomarkers Inform Clinical Decision-Making in Chronic Pain Management?

Hagedorn¹,

Gunn²,

Budwany³

et al. 2021

JPR

View full text Add to dashboard Cite

Objective Decision-making in chronic pain patients involves a combination of subjective and objective criteria, including patient history, physical examination, imaging, and patient response to prior treatments, clinical experience, probabilities, and recognition of patterns. However, there is a distinct lack of objective laboratory biomarkers in use in routine clinical care. The objective was to review the literature to identify and describe specific biomarkers in chronic pain management. Methods This is a narrative review of the literature regarding the use of laboratory biomarkers in chronic pain. A librarian-assisted literature search of the PubMed, Science Direct, and Google Scholar databases was performed and resulted in 304 possible manuscripts. We included manuscripts assessing laboratory collected biomarkers from urine, serum, cerebrospinal fluid, and saliva. After screening and review of the initial literature search results, a total of 75 manuscripts were included in the narrative review. Conclusion The studies reviewed suggested that specific biomarkers may help identify those patients at risk of disease development and function as a prognostic indicator for disease progression and treatment response. However, additional research is necessary before specific recommendations can be made, and current clinical decision-making is modified.

show abstract

Section: Literature Review Of Chronic Pain Biomarkersmentioning

confidence: 99%

“… Studied in urological chronic pelvic pain syndrome. [ 35 ] Vascular endothelial growth factor (VEGF, VEGF-R1) Plays important role in modulating pain. Also involved with vascular permeability and angiogenesis.…”

Section: Literature Review Of Chronic Pain Biomarkersmentioning

confidence: 99%

How Well Do Current Laboratory Biomarkers Inform Clinical Decision-Making in Chronic Pain Management?

Hagedorn¹,

Gunn²,

Budwany³

et al. 2021

JPR

View full text Add to dashboard Cite

show abstract

“…The published reports from our group have used ELISA to identify and validate urinary matrix metalloproteinases, neutrophil gelatinase-associated lipocalin, VEGF, and VEGFR1 in the context of UCPPS. These studies were able to discriminate between high and low levels of UCPPS severity and provide mechanistic insight into potential mechanisms underlying severity ( 2 ). Several of these molecules also correlated with longitudinal changes in symptom severity.…”

mentioning

confidence: 99%

The Urinary Proteomic Profile Implicates Key Regulators for Urologic Chronic Pelvic Pain Syndrome (UCPPS): A MAPP Research Network Study

Froehlich

Wang

Logvinenko

et al. 2022

Molecular & Cellular Proteomics

Self Cite

View full text Add to dashboard Cite

Urologic chronic pelvic pain syndrome (UCPPS) is a condition of unknown etiology characterized by pelvic pain and urinary frequency and/or urgency. As the proximal fluid of this syndrome, urine is an ideal candidate sample matrix for an unbiased study of UCPPS. In this study, a large, discovery-phase, TMT-based quantitative urinary proteomics analysis of 244 participants was performed. The participants included patients with UCPPS (n = 82), healthy controls (HC) (n = 94), and disparate chronic pain diseases, termed positive controls (PC) (n = 68). Using training and testing cohorts, we identified and validated a small and distinct set of proteins that distinguished UCPPS from HC (n = 9) and UCPPS from PC (n = 3). The validated UCPPS: HC proteins were predominantly extracellular matrix/extracellular matrix modifying or immunomodulatory/host defense in nature. Significantly varying proteins in the UCPPS: HC comparison were overrepresented by the members of several dysregulated biological processes including decreased immune cell migration, decreased development of epithelial tissue, and increased bleeding. Comparison with the PC cohort enabled the evaluation of UCPPS-specific upstream regulators, contrasting UCPPS with other conditions that cause chronic pain. Specific to UCPPS were alterations in the predicted signaling of several upstream regulators, including alpha-catenin, interleukin-6, epidermal growth factor, and transforming growth factor beta 1, among others. These findings advance our knowledge of the etiology of UCPPS and inform potential future clinical translation into a diagnostic panel for UCPPS.

show abstract

Markers of Tissue Deterioration and Pain on Earth and in Space

Patron,

Neset,

Mielkozorova

et al. 2024

JPR

View full text Add to dashboard Cite

Purpose Pain is an understudied physiological effect of spaceflight. Changes in inflammatory and tissue degradation markers are often associated with painful conditions. Our aim was to evaluate the changes in markers associated with tissue deterioration after a short-term spaceflight. Patients and Methods Plasma levels of markers for systemic inflammation and tissue degeneration markers were assessed in two astronauts before and within 24 h after the 17-day Axiom Space AX-1 mission. Results After the spaceflight, C-reactive protein (CRP) was reduced in both astronauts, while INFγ, GM-CSF, TNFα, BDNF, and all measured interleukins were consistently increased. Chemokines demonstrated variable changes, with consistent positive changes in CCL3, 4, 8, 22 and CXCL8, 9, 10, and consistent negative change in CCL8. Markers associated with tissue degradation and bone turnover demonstrated consistent increases in MMP1, MMP13, NTX and OPG, and consistent decreases in MMP3 and MMP9. Conclusion Spaceflight induced changes in the markers of systemic inflammation, tissue deterioration, and bone resorption in two astronauts after a short, 17-day, which were often consistent with those observed in painful conditions on Earth. However, some differences, such as a consistent decrease in CRP, were noted. All records for the effect of space travel on human health are critical for improving our understanding of the effect of this unique environment on humans.

show abstract

Association of Longitudinal Changes in Symptoms and Urinary Biomarkers in Patients with Urological Chronic Pelvic Pain Syndrome: A MAPP Research Network Study

Cited by 4 publications

References 0 publications

How Well Do Current Laboratory Biomarkers Inform Clinical Decision-Making in Chronic Pain Management?

How Well Do Current Laboratory Biomarkers Inform Clinical Decision-Making in Chronic Pain Management?

The Urinary Proteomic Profile Implicates Key Regulators for Urologic Chronic Pelvic Pain Syndrome (UCPPS): A MAPP Research Network Study

Markers of Tissue Deterioration and Pain on Earth and in Space

Contact Info

Product

Resources

About